<ѻýҕl>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survivalѻýҕl> Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<ѻýҕl>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemiaѻýҕl> OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<ѻýҕl>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLLѻýҕl> Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<ѻýҕl>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphomaѻýҕl> Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<ѻýҕl>Gene Therapy Resolves Severe Pain Events in Sickle Cell Diseaseѻýҕl> LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
<ѻýҕl>Can Dasatinib Dose Be Halved in Low-Risk CML?ѻýҕl> Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<ѻýҕl>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCLѻýҕl> Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<ѻýҕl>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/Bѻýҕl> Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<ѻýҕl>R-CHOP Toppled in First-Line DLBCL Trialѻýҕl> Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<ѻýҕl>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALLѻýҕl> One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<ѻýҕl>β-Thalassemia Patients Go Transfusion-Free With Gene Therapyѻýҕl> Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<ѻýҕl>R2 Maintenance for Elderly MCL Patients Worth the Risk?ѻýҕl> Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<ѻýҕl>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Ratesѻýҕl> Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<ѻýҕl>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphomaѻýҕl> Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<ѻýҕl>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-Tѻýҕl> Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<ѻýҕl>Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patientsѻýҕl> Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
<ѻýҕl>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patientsѻýҕl> Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<ѻýҕl>Pegylated Interferon Wins FDA Approval for Polycythemia Veraѻýҕl> Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<ѻýҕl>Is Multiple Myeloma a Greater Threat to Black Patients?ѻýҕl> Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
<ѻýҕl>A Gentler Standard for Acute Promyelocytic Leukemia in Kidsѻýҕl> ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
<ѻýҕl>Vaccinated Blood Cancer Patients Still at Risk for Severe COVID-19ѻýҕl> Those with hematologic malignancies also remain at higher risk of mortality as well Nov 08, 2021
<ѻýҕl>Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypesѻýҕl> New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
<ѻýҕl>FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemiaѻýҕl> Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
<ѻýҕl>Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemiaѻýҕl> Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
<ѻýҕl>Longer Hydroxyurea Tied to Improved Sickle-Cell Heart Issuesѻýҕl> Kids on treatment for less than 1 year had a significantly greater prevalence of LV dilation Sep 16, 2021
<ѻýҕl>9/11 Responders Face Higher Risk of Multiple Cancersѻýҕl> Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
<ѻýҕl>Life Expectancy Still Lower for Blood or Marrow Transplant Recipientsѻýҕl> Although late mortality has decreased over the past 40 years Sep 09, 2021
<ѻýҕl>Liver Toxicity in Gene Therapy Trials Could Merit Stricter Entry Criteriaѻýҕl> FDA panel weighs in on lower vector doses and role of animal studies Sep 03, 2021
<ѻýҕl>Adding Mycophenolate Mofetil Improves Outcomes in ITPѻýҕl> "Somewhat decreased" quality of life, however, British study finds Sep 01, 2021
<ѻýҕl>Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphomaѻýҕl> Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
<ѻýҕl>Are Hemoglobin Cutoffs for Anemia Outdated?ѻýҕl> A growing call for WHO criteria to be tightened Aug 06, 2021
<ѻýҕl>Woman Develops Tiny Blood Spots on Her Body After COVID Shotѻýҕl> Case highlights need for quick diagnosis and management of rare disorder Aug 05, 2021
<ѻýҕl>Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemiaѻýҕl> Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
<ѻýҕl>Add-On Venetoclax Promising in Younger, Fit AML Patientsѻýҕl> "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
<ѻýҕl>Call in the T-Cell Cavalry to Fight COVID in the Immunocompromisedѻýҕl> Preliminary research suggests immunotherapy could play role in protecting vaccine non-responders Jul 29, 2021
<ѻýҕl>Shingrix OK'd for Immunocompromised Adultsѻýҕl> CDC's vaccine committee currently discussing vaccine for this population, manufacturer says Jul 26, 2021
<ѻýҕl>Keytruda Before, After Surgery Improves Outcome in TNBCѻýҕl> Results from KEYNOTE-522 show "practice-changing" impact on EFS Jul 15, 2021
<ѻýҕl>Raise a Glass? Study Tallies Cancer Cases From Boozeѻýҕl> Heavy drinking habits accounted for about half of new alcohol-associated cases Jul 13, 2021
<ѻýҕl>Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer?ѻýҕl> Use of chemo reduced radiation-induced cancers, and may prolong OS in low-PSA subgroup Jul 07, 2021
<ѻýҕl>Infusion Centers or EDs for Sickle Cell Crises?ѻýҕl> Adults with SCD treated in infusion centers had improved outcomes in three key measures Jul 06, 2021